| Literature DB >> 21603264 |
Karrie E Wheatley1, Leticia M Nogueira, Susan N Perkins, Stephen D Hursting.
Abstract
We tested the hypothesis that obesity reversal by calorie restriction (CR) versus treadmill exercise (EX) differentially modulates adipose gene expression using 48 female C57BL/6 mice administered a diet-induced obesity (DIO) regimen for 8 weeks, then randomized to receive for 8 weeks either: (1) a control (AIN-76A) diet, fed ad libitum (DIO control); (2) a 30% CR regimen; (3) a treadmill EX regimen (with AIN-76A diet fed ad libitum); or (4) continuation of the DIO diet. Relative to the DIO controls, both CR and EX reduced adiposity by 35-40% and serum leptin levels by 80%, but only CR increased adiponectin and insulin sensitivity. Gene expression microarray analysis of visceral white adipose tissue revealed 209 genes responsive to both CR and EX, relative to the DIO group. However, CR uniquely altered expression of an additional 496 genes, whereas only 20 were uniquely affected by EX. Of the genes distinctly responsive to CR, 17 related to carbohydrate metabolism and glucose transport, including glucose transporter (GLUT) 4. Chromatin immunoprecipitation assays of the Glut4 promoter revealed that, relative to the DIO controls, CR significantly increased histone 4 acetylation, suggesting epigenetic regulation may underlie some of the differential effects of CR versus EX on the adipose transcriptome.Entities:
Year: 2011 PMID: 21603264 PMCID: PMC3092555 DOI: 10.1155/2011/265417
Source DB: PubMed Journal: J Obes ISSN: 2090-0708
Body composition after 8 weeks of DIO followed by 8 weeks of control diet, exercise, or calorie restriction.
| Group | Body weight week 9 (g) | Body weight week 16 (g) | Percent body fat (%) | Lean mass (g) |
|---|---|---|---|---|
| DIO Control | 30.1 ± 0.9a | 30.8. ± 0.6a | 51.1 ± 3.8a | 12.6 ± 0.2a |
| Exercise | 29.3 ± 0.6a | 26.0 ± 0.9b | 38.9 ± 2.7b | 13.6 ± 0.2b |
| Calorie Restriction | 31.3± 0.6a | 19.9 ± 0.5c | 33.7 ± 1.4b | 10.5 ± 0.1c |
| ContinuousDIO* | 30.3 ± 1.2a | 33.2± 1.5a | 57.3 ± 2.9a | 11.8 ± 0.2d |
Data are presented mean ± SEM. Significant differences (P < .05) beween data within a column are indicated by different superscripts; n = 12/group.
Figure 1Effect of calorie restriction or exercise in diet-induced obese mice on serum hormones and glucose tolerance. (a) Animal study design for gene expression microarray experiments. (b) Serum leptin levels, (c) serum adiponectin levels, and (d) serum insulin levels after 8 weeks of intervention, (n = 11 for DIO group; n = 10 for CR group; n = 10 for EX group). (e) Blood glucose concentrations during a glucose tolerance after 7 weeks of intervention. Data shown are mean ± SE. DIO (●), EX (), CR (□), n = 12/group. Significance (P ≤ .05) between groups is denoted by different letters.
Figure 2Effect of weight loss induced by calorie restriction or exercise on mRNA expression in VWAT. (a) Venn Diagram of genes differentially expressed by CR and EX compared to DIO controls. (b) Classification of genes targeted by both CR and EX. (c) Heat map of genes related to metabolic processes affected by both CR and EX. (d) Classification of genes targeted uniquely by CR (n = 6/group).
Transcriptional changes in response to calorie restriction or exercise in visceral white adipose tissue.
| Gene Symbol | Gene title | Fold change | |
|---|---|---|---|
| Cellular lipid metabolic process | CR × DIO | ||
| Slc27a1 | Solute carrier family 27 (fatty acid transporter) | 2.53 | up |
| Fads2 | Fatty acid desaturase 2 | 2.18 | up |
| Ces3 | Carboxylesterase 3 | 2.51 | up |
| Sult1a1 | Sulfotransferase family 1A | 2.22 | up |
| Ptges | Prostaglandin E synthase | 2.25 | up |
| Sgpp1 | Sphingosine-1-phosphate phosphatase 1 | 2.73 | down |
| Echs1 | Enoyl Coenzyme A hydratase | 2.00 | up |
| Hsd11b1 | Hydroxysteroid 11-beta dehydrogenase 1 | 3.28 | up |
| Apoc3 | Apolipoprotein C-III | 5.71 | up |
| Srebf1* | Sterol regulatory element binding transcription factor 1 | 2.98 | up |
| Aldh1a7 | Aldehyde dehydrogenase family 1 | 2.18 | up |
| Hpgd | Hydroxyprostaglandin dehydrogenase 15 (NAD) | 2.09 | down |
| Rdh11 | Retinol dehydrogenase 11 | 4.59 | up |
| Rarres2 | Retinoic acid receptor responder (tazarotene induced) 2 | 2.61 | down |
| Nsdhl* | NAD(P) dependent steroid dehydrogenase-like | 2.65 | up |
| Gpam | Glycerol-3-phosphate acyltransferase | 2.06 | up |
| Hmgcs1* | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 | 3.01 | down |
| Abat | 4-aminobutyrate aminotransferase | 2.88 | down |
| Sorl1 | Sortilin-related receptor | 2.77 | up |
| Pip4k2a | Phosphatidylinositol-5-phosphate 4-kinase | 2.02 | down |
| Acaca | Acetyl-Coenzyme A carboxylase alpha | 4.60 | up |
| Tm7sf2* | Transmembrane 7 superfamily member 2 | 3.69 | up |
| Sc5d* | Sterol-C5-desaturase | 2.11 | up |
| Fdft1* | Farnesyl diphosphate farnesyl transferase 1 | 2.68 | up |
| Hsd17b12* | Hydroxysteroid (17-beta) dehydrogenase 12 | 2.17 | up |
| Pcx* | Pyruvate carboxylase | 2.88 | up |
| Cellular carbohydrate metabolic process | |||
| Fn3k | Fructosamine 3 kinase | 4.05 | up |
| Chst1* | Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 | 2.00 | up |
| Dlat | Dihydrolipoamide S-acetyltransferase | 2.59 | up |
| Pkm2 | Pyruvate kinase | 2.37 | up |
| Pmm1 | Phosphomannomutase 1 | 2.72 | up |
| Ppp1r1a | Protein phosphatase 1 | 2.61 | up |
| Pgd | Phosphogluconate dehydrogenase | 2.40 | up |
| Agl | Amylo-1 | 2.16 | up |
| Oxct1 | 3-oxoacid CoA transferase 1 | 2.17 | down |
| Pdk1 | Pyruvate dehydrogenase kinase | 3.07 | up |
| Gpd1 | Glycerol-3-phosphate dehydrogenase 1 (soluble) | 2.02 | up |
| Taldo1 | Transaldolase 1 | 2.03 | up |
| Glucose transport | |||
| Sh2b2* | SH2B adaptor protein 2 | 3.26 | up |
| Slc2a4 | Solute carrier family 2 (facilitated glucose transporter) | 3.43 | up |
| Pcx* | Pyruvate carboxylase | 2.88 | up |
| Klf15 | Kruppel-like factor 15 | 2.36 | up |
| Immune response | CR × DIO | ||
| Malt1 | Mucosa associated lymphoid tissue Lymphoma translocation gene 1 | 2.55 | down |
| Bcl6* | B-cell leukemia/lymphoma 6 | 2.90 | down |
| Clec7a* | C-type lectin domain family 7 | 2.89 | down |
| Cfb | Complement factor B | 2.53 | down |
| Cd55* | CD55 antigen | 2.25 | Down |
| Thy1 | Thymus cell antigen 1 | 2.44 | down |
| Biosynthesis of Steroids | |||
| Lss | Lanosterol synthase | 2.13 | up |
| Hmgcs1* | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 | 3.01 | down |
| Tm7sf2* | Transmembrane 7 superfamily member 2 | 3.69 | up |
| Sc5d* | Sterol-C5-desaturase | 2.11 | up |
| Fdft1* | Farnesyl diphosphate farnesyl transferase 1 | 2.68 | up |
| Hsd17b12* | Hydroxysteroid (17-beta) dehydrogenase 12 | 2.17 | up |
| Nsdhl* | NAD(P) dependent steroid dehydrogenase-like | 2.65 | up |
| Sh2b2* | SH2B adaptor protein 2 | 3.26 | up |
| Stress response | |||
| Thbs1 | Thrombospondin 1 | 2.29 | down |
| Tfpi2 | Tissue factor pathway inhibitor 2 | 4.32 | down |
| Gp1bb | Glycoprotein Ib | 2.06 | up |
| Taok3 | TAO kinase 3 | 2.21 | down |
| Sod3 | Superoxide dismutase 3 | 2.17 | down |
| Dusp10 | Dual specificity phosphatase 10 | 2.62 | down |
| Adrb3 | Adrenergic receptor | 2.09 | up |
| F2r | Coagulation factor II (thrombin) receptor | 2.22 | down |
| Ccnd1 | Cyclin D1 | 2.91 | down |
| Evl | Ena-vasodilator stimulated phosphoprotein | 2.32 | down |
| Ctsb | Cathepsin B | 2.00 | down |
| Ly86 | Lymphocyte antigen 86 | 2.65 | down |
| Fabp4 | Fatty acid binding protein 4 | 2.03 | up |
| Rad50 | RAD50 homolog (S. cerevisiae) | 2.27 | down |
| Tsc22d2 | TSC22 domain family 2 | 2.41 | down |
| Ptger3 | Prostaglandin E receptor 3 (subtype EP3) | 2.21 | up |
| Lcp1 | Lymphocyte cytosolic protein 1 | 3.06 | down |
| Pros1 | Protein S (alpha) | 2.09 | down |
| Hspa12a | Heat shock protein 12A | 2.40 | down |
| Anxa2 | Annexin A2 | 2.01 | down |
| Uhrf1 | Ubiquitin-like | 2.84 | down |
| Cdkn1a | Cyclin-dependent kinase inhibitor 1A (P21) | 2.28 | down |
| Srebf1* | Sterol regulatory element binding transcription factor 1 | 2.98 | up |
| Chst1* | Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 | 2.00 | up |
| Bcl6* | B-cell leukemia/lymphoma 6 | 2.90 | down |
| Clec7a* | C-type lectin domain family 7 | 2.89 | down |
| Cd55* | CD55 antigen | 2.25 | down |
| Exercise unique | |||
| Mitochondrial Transport | EX × DIO | ||
| Ucp1 | Uncoupling protein | 8.94 | up |
| Ucp2 | Uncoupling protein 2 | 2.09 | down |
*Genes represented in two different categories.
Figure 3Confirmation of microarray data analysis of mRNA expression in VWAT. Expression of mRNA transcripts in VWAT from DIO control, CR and EX mice (n = 7/group). (a) Leptin (Lep), (b) Uncoupling protein 1 (Ucp1), (c) Uncoupling protein 2 (Ucp2), (d) Solute carrier 2, family 4 (Slc2a4) (e) ATP-citrate lyase (Acly), and (f) SH2B adapter protein 2 (Sh2b2) (Data shown are mean ± SE, *(P ≤ .05)).
Figure 4Lean phenotype is associated with lower blood glucose levels and elevated levels of Glut4 mRNA relative to control mice. (a) Study design for chromosomal immunoprecipitation experiments. (b) Average body weight of mice on DIO, overweight (control AIN-76A) diet, or a lean (CR) regimen to generate obese, overweight or lean mice (n = 5/group). Data shown are mean ± SE. (c) Fasting blood glucose levels of mice after 8 weeks of respective dietary regimen (n = 5/group). Data shown are mean ± SE. Significance (P < .05) between groups is denoted by different letters. (d) Relative mRNA expression of Glut4 in VWAT (n = 5/group). Significance (P < .05) between groups is denoted by different letters.
Figure 5Calorie restriction increases histone H4 acetylation at the GLUT 4 promoter. (a) Relative quantification of Glut4 DNA immunoprecipitated with anti-trimethyl H4 antibody. (b) Relative quantification of Glut4 DNA immunoprecipitated with anti-acetyl H4 antibody (n = 3/group). Data shown are mean ± SE, *(P ≤ 0.05).